RxDoctor Payments Data

Patricia Thompson, MD

Pediatrics · Magnolia, TXNPI 1518980465

Payments from drug & device makers

$12,757in general payments, 2019–2025

Across 787 payments — averaging $16.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$1K
  • Boehringer Ingelheim$991
  • Lilly USA, LLC$900
  • GSK$804
  • AbbVie$760
  • plus $6K from 49 others

What the payments were for

  • Food & beverage$12,725100%
  • Education$320%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,757 in reported general payments places this provider in the 95th percentile of 5,361 pediatrics providers in Texas.

See all pediatrics providers in Texas

Medicare billing

Part B allowed, 2024
$108,379
Medicare patients
366
Services billed
1,555

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide164$185,750
JardianceEmpagliflozin80$97,142
EliquisApixaban48$68,948
MounjaroTirzepatide42$64,330
XareltoRivaroxaban21$27,899
JanuviaSitagliptin Phosphate21$25,763
TrulicityDulaglutide21$25,750
MyrbetriqMirabegron26$22,553
FarxigaDapagliflozin Propanediol18$17,925
JanumetSitagliptin Phos/Metformin Hcl18$14,798
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$11,033
Repatha SureclickEvolocumab14$9,505
Lantus SolostarInsulin Glargine,hum.Rec.Anlog49$5,802
Atorvastatin Calcium587$5,445
Combivent RespimatIpratropium/Albuterol Sulfate11$5,030

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$2,295$185,750164 claims
Boehringer IngelheimJardiance, Combivent Respimat$991$102,17291 claims
Lilly USA, LLCMounjaro, Trulicity$900$90,08163 claims
PfizerEliquis$441$68,94848 claims
MerckJanuvia, Janumet$239$40,56139 claims
Johnson & JohnsonXarelto$183$27,89921 claims
Astellas Pharma US IncMyrbetriq$127$22,55326 claims
AstraZenecaFarxiga, Symbicort$1,222$20,88929 claims
GSKTrelegy Ellipta, Arnuity Ellipta$804$14,04329 claims
AbbVieSynthroid, Armour Thyroid$760$6,407127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,361 pediatrics providers in Texas.

Other pediatrics in Magnolia

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →